⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for lymphoid malignancy

Every month we try and update this database with for lymphoid malignancy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With CancerNCT00982566
Lymphoid Malign...
Solid Tumors
ABT-263
ABT-263
ABT-263
ABT-263
18 Years - AbbVie
Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid MalignanciesNCT00048737
Lymphoma
Leukemia
Zevalin Radioim...
Rituximab
Fludarabine
Cyclophosphamid...
Allogeneic Stem...
18 Years - 70 YearsM.D. Anderson Cancer Center
Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow TransplantsNCT00001830
Chronic Lymphoc...
Graft vs Host D...
Hodgkin's Disea...
Multiple Myelom...
Non Hodgkin's L...
Th2 cells in al...
Th2 Cells
12 Years - 75 YearsNational Institutes of Health Clinical Center (CC)
Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid MalignanciesNCT00820508
Hematological D...
Lymphoid Malign...
CHR-2845
18 Years - Chroma Therapeutics
Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow TransplantsNCT00001830
Chronic Lymphoc...
Graft vs Host D...
Hodgkin's Disea...
Multiple Myelom...
Non Hodgkin's L...
Th2 cells in al...
Th2 Cells
12 Years - 75 YearsNational Institutes of Health Clinical Center (CC)
Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte LeukemiaNCT03759184
Leukemia
Lymphocytic
Chronic
B-Cell
rhIL-15
rhIL-15
Obinutuzumab
18 Years - National Institutes of Health Clinical Center (CC)
Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte LeukemiaNCT03759184
Leukemia
Lymphocytic
Chronic
B-Cell
rhIL-15
rhIL-15
Obinutuzumab
18 Years - National Institutes of Health Clinical Center (CC)
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: